Recent Advances in Trigeminal Neuralgia and Its Management: A Narrative Review

IF 0.2 Q4 ANESTHESIOLOGY Journal of Neuroanaesthesiology and Critical Care Pub Date : 2021-05-24 DOI:10.1055/s-0041-1726152
Sourav Burman, Ankur Khandelwal, A. Chaturvedi
{"title":"Recent Advances in Trigeminal Neuralgia and Its Management: A Narrative Review","authors":"Sourav Burman, Ankur Khandelwal, A. Chaturvedi","doi":"10.1055/s-0041-1726152","DOIUrl":null,"url":null,"abstract":"Abstract Trigeminal neuralgia (TN) is a chronic facial pain condition that affects one or more divisions of the trigeminal nerve (5th cranial nerve). It can be idiopathic, primary, or secondary. The cornerstone of the therapy has been antiepileptic medications, peripheral nerve blocks with various neurolytic agents, and surgical procedures. With the advent of newer technologies, minimally invasive neurolytic techniques like low-level laser therapy and ozone injection have revolutionized the management of TN. Novel drugs like vixotrigine and eslicarbazepine have been promising in reducing the frequency and severity of attacks. Inhaled carbon dioxide too has shown promising results in initial trials. Neuromodulation has given robust data in controlling neuralgic pain especially refractory to medical management. Pulsed radiofrequency has been used with increasing success and the side effects like dysesthesia and paresthesia are less. Cryotherapy, neural prolotherapy, and fiber knife techniques have helped us believe that TN can be controlled and cured. The need of the hour is to develop and explore newer modalities for trigeminal neuralgia treatment with minimum side effects. In this narrative review, we have tried to shed light into the newer modalities of treatment of TN along with new clinical classification for better disease recognition and management.","PeriodicalId":16574,"journal":{"name":"Journal of Neuroanaesthesiology and Critical Care","volume":"8 1","pages":"112 - 117"},"PeriodicalIF":0.2000,"publicationDate":"2021-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-0041-1726152","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuroanaesthesiology and Critical Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0041-1726152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Abstract Trigeminal neuralgia (TN) is a chronic facial pain condition that affects one or more divisions of the trigeminal nerve (5th cranial nerve). It can be idiopathic, primary, or secondary. The cornerstone of the therapy has been antiepileptic medications, peripheral nerve blocks with various neurolytic agents, and surgical procedures. With the advent of newer technologies, minimally invasive neurolytic techniques like low-level laser therapy and ozone injection have revolutionized the management of TN. Novel drugs like vixotrigine and eslicarbazepine have been promising in reducing the frequency and severity of attacks. Inhaled carbon dioxide too has shown promising results in initial trials. Neuromodulation has given robust data in controlling neuralgic pain especially refractory to medical management. Pulsed radiofrequency has been used with increasing success and the side effects like dysesthesia and paresthesia are less. Cryotherapy, neural prolotherapy, and fiber knife techniques have helped us believe that TN can be controlled and cured. The need of the hour is to develop and explore newer modalities for trigeminal neuralgia treatment with minimum side effects. In this narrative review, we have tried to shed light into the newer modalities of treatment of TN along with new clinical classification for better disease recognition and management.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
三叉神经痛及其治疗的最新进展:叙事综述
摘要三叉神经痛(TN)是一种影响三叉神经(第五颅神经)一个或多个分支的慢性面部疼痛状况。它可以是特发性、原发性或继发性。该疗法的基石是抗癫痫药物、使用各种神经溶解剂的外周神经阻滞和外科手术。随着新技术的出现,微创神经溶解技术,如低水平激光治疗和臭氧注射,已经彻底改变了TN的管理。新药物,如vixotrigin和eslicarbazepine,在降低发作频率和严重程度方面很有希望。吸入的二氧化碳在最初的试验中也显示出了有希望的结果。神经调控在控制神经疼痛方面提供了可靠的数据,尤其是在医疗管理方面。脉冲射频的使用越来越成功,而且感觉障碍和感觉异常等副作用也越来越少。冷冻疗法、神经增殖疗法和纤维刀技术帮助我们相信TN是可以控制和治愈的。现在的需要是开发和探索副作用最小的三叉神经痛治疗新方法。在这篇叙述性综述中,我们试图阐明TN的新治疗模式以及新的临床分类,以更好地识别和管理疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Neuroanaesthesiology and Critical Care
Journal of Neuroanaesthesiology and Critical Care Medicine-Critical Care and Intensive Care Medicine
CiteScore
0.50
自引率
0.00%
发文量
29
审稿时长
15 weeks
期刊最新文献
High-Flow Nasal Oxygen Therapy for Management of Postoperative Pneumocephalus Perioperative Outcomes of Hyperlactatemia during Craniotomy: A Systematic Review and Meta-Analysis of 1,832 Patients Failure of Sequential Compression Device Detected by Neuromonitoring during Minimally Invasive Posterior Scoliosis Surgery Persistent Post-Extubation Stridor in an Intensive Care Unit: A Decision Dilemma Awake Aneurysm Clipping: Challenges Conquered
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1